1.A clinical study on Leucogen tablets therapy efficacy during PEGα-Interferon and α-Interferon in chronic hepatitis B
Hong-Fei ZHANG ; Li-Min WANG ; Yi DONG ; XUZhi-qiang ; Da-Wei CHEN ; Yu GAN ; Fu-Chuan WANG ; Shi-Shu ZHU
Chinese Journal of Experimental and Clinical Virology 2012;26(2):111-113
Objective To discuss the efficacy of Leucogen tablets treatment lessen the hematological reaction and raise the efficacy therapy of interferon in chronic hepatitis B treated with PEG-αinterferon and α interferon.Methods A total of 395 patients with HBeAg-positive chronic hepatitis B (CHB) inpatients from January 2002 to February 2011.Group:All the patients were assigned to A or B according as during the treatment added Leucogen tablets or not.Results ( 1 ) All of 35.9% patients had neutrophil counts decrease under 1 × 109/L,A group had 29.6%,B had 42.8% patients,P =0.01 ;neutrophil counts≤0.75 × 109/L A group had 12.6%,B group had 26.4%,P =0.02; neutrophil counts≤ 0.5 × 109/L A group had 4.8 %,B group had 16.4%,P =0.04.(2) A group had 8.2% patients interferon-α dose decreased,all the patient finished the period of therapy.B group had 23.3% patients interferon-α dose decreased,2.1% of patients had paused.A group had 40.3% of patients interferon-α beyond conventional dose,B group had only 5.2%.(3)All of 9.8% patients had hematoblast decrease under 100 × 109/L,A group had 8.7%,B had 11.1% patients;hematoblast≤ 80 × 109/L A group had 5.3%,B group had 7.9% ;hematoblast ≤ 50 × 109/L A group had 1.0%,B group had 2.6%.A group had the trend of reducing hematoblast decrease.(4) At the end of therapy A group had 67.4% patients HBVDNA < 100IU/ml,54.3% e antigen negative,40.7% e antigen conversed; B group had 53.9%,41.2%,26.9%,P was respectively 0.02,0.01,0.01.Conclusion Leucogen tablets treatment and prevention interferon-α-related neutrophil counts hematological reaction in CHB treated with a-interferon,and had the trend of reducing interferon-αrelated hematoblast decrease,farther improved the efficacy of α-interferon treatment CHB.
2.Preparation quality control and clinical application observation of pooled platelets with leukocytes reduced
Min GUO ; Jianmin LI ; Jianhui LIU ; Ning YANG ; Jing ZHANG ; Yuqiu LI ; Fei CHENG ; Xuzhi LIU ; Qiang HE ; Miao HE ; Wenjuan YANG
Chinese Journal of Blood Transfusion 2023;36(11):1025-1028
【Objective】 To investigate the preparation quality and clinical application effect of pooled platelets with leukocytes reduced. 【Methods】 The quality and clinical effect of the buffy-coated method prepared pooled platelets leukocytes reduced (experimental group, n=40) and apheresis platelets leukocytes reduced (control group, n=40) were compared. 【Results】 The platelet volume (mL), platelet count (×1011), red blood cell contamination (×108) and residual white blood cell (×106) of the experimental group and control group were 278.90±7.92 vs 276.52±8.01, 2.66±0.09 vs 2.66±0.83, 0.54±0.42 vs 0.83±0.84, 0.29±0.54 vs 0.27±0.51, respectively, with no significant difference. The results of bacterial culture were negative, all met the requirements of relevant national standards. In addition, the CCI (×103, 24 h) and PPR (%) were 15.11±9.86 vs 14.61±12.55 and 54.23±18.70 vs 61.41±19.09 respectively, with no significant difference, indicating a certain degree of therapeutic effect. 【Conclusion】 The quality and clinical therapeutic effect of pooled platelets leukocytes reduced were consistent with that of apheresis platelets leukocytes reduced.